Voyager Therapeutics racks up $60 mln
Cambridge, Massachusetts-based Voyager Therapeutics, a gene therapy company focused on treating central nervous system diseases, has closed $60 million in Series B funding. Brookside Capital and Partner Fund Management led the round with participation from other investors that included Wellington Management Company LLP and Casdin Capital LLC.
13 April 2015•2 mins read
